ISRCTN74084226
Completed
Phase 2
A trial of de-escalation and stopping treatment in chronic myeloid leukaemia patients with excellent responses to tyrosine kinase inhibitor therapy (De-Escalation and Stopping Treatment of Imatinib, Nilotinib or sprYcel in chronic myeloid leukaemia) (DESTINY)
niversity of Liverpool (UK)0 sites168 target enrollmentJune 12, 2013
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Topic: National Cancer Research Network
- Sponsor
- niversity of Liverpool (UK)
- Enrollment
- 168
- Status
- Completed
- Last Updated
- 8 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. CML in first chronic phase
- •2\. Demonstration of BCR\-ABL1 positivity at or shortly after original diagnosis\*
- •3\. Written informed consent
- •4\. Must have received TKI treatment for at least 3 years
- •5\. At least 3 molecular results over the preceding 12 months, that fit either of the following groups (results from any UK lab are acceptable):
- •5\.1\. (MR4 group) all the available BCR\-ABL1 molecular results over the preceding 12 months are in MR4 (MR4 is defined as a BCRABL1/ABL1 ratio of zero, with at least 10,000 ABL1 control transcripts)
- •5\.2\. (MMR group) some or all BCR\-ABL1 molecular results are in MMR (BCRABL1/ ABL1 ratio of 0\.1% or less, but not zero, with at least 10,000 ABL1 control transcripts). If the results over the preceding 12 months are a mix of MMR and undetectable BCR\-ABL1, then the patient is eligible for the MMR but not the MR4 group.
- •\*Patients who are Philadelphia chromosome (Ph) negative (or whose Ph status is not known) are eligible. Patients who do not have a standard BCR\-ABL1 fusion transcript (i.e. other than e13a2 or e14a2, also known as b2a2 and b3a2\) are eligible, but before screening the patient, contact should be made with Prof Foroni at Imperial College (see contacts) since specialised quantitative molecular assessment will be required.
- •Target Gender: Male \& Female; Lower Age Limit 18 years
Exclusion Criteria
- •1\. Age under 18
- •2\. Life expectancy is predicted to be less than 37 months because of intercurrent illness
- •3\. Presence of serious concomitant illness (e.g. heart, renal, respiratory or active malignant disease) that might preclude completion of the study
- •4\. CML in accelerated phase or blast crisis at any time
- •5\. Any molecular result during the preceding 12 months that is not in either MMR or MR4
- •6\. Treatment with higher than standard TKI doses (?standard? is defined as imatinib 400mg daily, nilotinib 400mg twice daily or dasatinib 100mg daily)
- •7\. Patients who switched previous licensed TKI treatment (imatinib, nilotinib or dasatinib) twice or more because of intolerance
- •8\. Patients who switched previous licensed TKI treatment (imatinib, nilotinib or dasatinib) because of resistance
- •9\. Patients treated with lower than standard TKI doses (imatinib 400mg daily, nilotinib 400mg twice daily or dasatinib 100mg daily) for tolerance reasons may be included, but will de\-escalate to the same doses as for standard dose patients and will be analysed separately, as they could be seen as undertreated
- •10\. Previous treatment with ponatinib or bosutinib. Patients who received interferon prior to commencing TKI (even if resistant to their interferon) are eligible, provided their response to TKI fits the entry criteria.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, Not Recruiting
Phase 1
A trial of de-escalation and stopping treatment in chronic myeloid leukaemia patients with excellent responses to tyrosine kinase inhibitor therapy DESTINY (De- Escalation and Stopping Treatment of Imatinib, Nilotinib or sprYcel in chronic myeloid leukaemia)Chronic myeloid leukaemiaMedDRA version: 16.0 Level: LLT Classification code 10009015 Term: Chronic myeloid leukemia System Organ Class: 100000004864MedDRA version: 16.0 Level: LLT Classification code 10009016 Term: Chronic myeloid leukemia in remission System Organ Class: 100000004864Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]EUCTR2012-004025-24-GBniversity of Liverpool174
Completed
Phase 4
A study on the procedure for treatment switch to epoetin beta pegol in the treatment of renal anemia in maintenance hemodialysis patientsRenal Anemia Patients on HemodialysisJPRN-UMIN000008090Faculty of medicine, University of Miyazaki30
Completed
Phase 3
Efficacy of WARTNER anti-wart local drug on genital wartsGenital wart.Anogenital (venereal) wartsIRCT138811073200N1Manoosha-Daru20
Active, Not Recruiting
Phase 1
Study on effectiveness of Flutiform® asthma inhalerAsthmaMedDRA version: 16.1Level: PTClassification code 10003553Term: AsthmaSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersMedDRA version: 16.1Level: PTClassification code 10038683Term: Respiratory disorderSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersTherapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]EUCTR2013-005365-39-GBResearch in Real-Life Ltd224
Active, Not Recruiting
Phase 1
A randomised, controlled trial to compare the safety and effectiveness of steroid tape with silver nitrate therapy, the current standard treatment for patients who have over-granulating tissue of their periotoneal dialysis catheter exit site.Over-granulation of peritoneal dialysis exit site in patients with End Stage Renal FailureMedDRA version: 18.0 Level: PT Classification code 10034660 Term: Peritoneal dialysis System Organ Class: 10042613 - Surgical and medical proceduresMedDRA version: 18.0 Level: LLT Classification code 10008831 Term: Chronic ambulatory peritoneal dialysis System Organ Class: 10042613 - Surgical and medical proceduresMedDRA version: 18.0 Level: LLT Classification code 10067974 Term: Automated peritoneal dialysis System Organ Class: 10042613 - Surgical and medical proceduresMedDRA version: 18.0 Level: PT Classification code 10067594 Term: Peritoneal dialysis complication System Organ Class: 10022117 - Injury, poisoning and procedural complicationsMedDRA version: 18.0 Level: LLT Classification code 10064116 Term: Continuous ambulatory peritoneal dialysis System Organ Class: 10042613 - Surgical and medical proceduresTherapeutic area: Body processes [G] - Biological Phenomena [G16]EUCTR2013-003867-76-GBniversity Hospitals Birmingham NHS Foundation Trust80